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A 14-year-old boy was referred to our division with a diagnosis 
of ‘progressive myopathy with psoriasis’ after a normal calf 
muscle biopsy excluded a previously suspected diagnosis 
of muscular dystrophy. The referring clinician had rejected 
a diagnosis of inflammatory myositis, based on repeatedly 
normal serum creatine kinase (CK) levels. Described as a 
‘lazy child’ who refused to play games such as soccer, he had 
developed increasing weakness over 3 years, a rash and, more 
recently, hard painless lumps in both axillae and groins. The 
weakness affected proximal limbs, resulting in difficulty with 
standing up from a low chair, getting out of bed and walking 
more than 200 meters. Climbing stairs was a challenge, and he 
could not carry objects such as grocery bags.
He demonstrated classic Gottron’s lesions on both hands, 
subcutaneous calcinosis in both axillae and groins, and a 
shawl sign on the back of his neck, associated with a diffuse 
erythematous, poikilodermatous and sclerodermoid rash, with 
atrophic skin involving the face, arms, forearms and legs. He 
had bilateral elbow flexion contractures (Fig. 1). His thigh and 
calf muscles were atrophic, with marked proximal myopathy 
and inability to stand up from a chair with arms folded or to 
rise from a recumbent position. Nailfold capillaroscopy showed 
dilated, tortuous, haemorrhagic vessels with telangiectasia and 
drop-out. His vital capacity and other systems were normal. 
His serum CK was 108 (normal <140 units/litre (U/l)), and 
electromyography showed myopathic units (low amplitude, 
short duration, polyphasic) with evidence of active denervation 
(fibrillation potentials and positive sharp waves) consistent 
with an active inflammatory myositis. Dermatomyositis 
(DM) was diagnosed, and the patient was treated with oral 
prednisone, with good improvement in muscle strength and 
enhanced performance.
Discussion
In 1863, Wagner first recognised dermatomyositis/
polymyositis. Unverricht, in 1891, first described 
dermatomyositis as we know it today. Idiopathic inflammatory 
myopathies, comprising dermatomyositis, polymyositis 
and inclusion body myositis,1 represent the largest group of 
acquired and potentially treatable causes of skeletal muscle 
weakness. Childhood or adolescent DM is an uncommon 
inflammatory disease classically encompassing hallmark 
cutaneous changes, proximal muscle weakness and laboratory 
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Fig. 1. Diagnostic clinical features in the patient (with permission from him and his





Fig. 1. Diagnostic clinical features in the patient (with permission from 
him and his mother). A: erythematous poikilode at us ras  on face (fore-
head and malar region); B: shawl sign on the back of his neck; C: atrophic 
calf muscles with rash on legs; D: wasting of the thigh muscles with a 
diffuse erythematous rash; E: classic Gottron’s lesions on finger joints; 
F: diffuse erythematous, poikilodermatous and scleredermoid rash, with 
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Our case of juvenile myopathic dermatomyositis was 
unrecognised because of a falsely normal serum CK level and 
a muscle biopsy in a relatively spared muscle. The CK is the 
most widely used and most sensitive and specific diagnostic 
test, but it is not the most useful in monitoring disease activity 
and response to treatment.3 An elevated CK is seen in 80 - 95% 
of adult DM patients,3 and in only two-thirds of patients with 
juvenile DM.2 Although the mean CK elevation is usually 
tenfold, the level does not always correlate with disease 
activity,4 and particularly not in juvenile subjects with DM.2 
Hence, other markers of muscle disease should be looked 
for when DM is suspected but the CK is not elevated (e.g. 
aldolase, aspartate transaminase, type 1 and type 5 lactate 
dehydrogenase isoenzymes, carbonic anhydrase III, myoglobin, 
troponin I, troponin T, and glutamate pyruvate transaminases).5
In the context of a myositis, a normal CK may reflect 
burnt-out disease,6 the presence of an inhibitor7 or co-morbid 
systemic lupus erythematosus and rheumatoid arthritis.4,8 
In juvenile DM the interpretation of the CK needs to be 
individualised. Although a normal CK with active DM often 
has a poorer prognosis,8 DM is a treatable and potentially 
reversible form of muscle weakness that, unrecognised, may 
have grave consequences. Our case highlights the importance 
of not relying solely on CK for diagnosing the condition, and 
that a trial of steroids should be considered in subjects with 
inflammatory myopathies, despite low or normal CK levels.
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The ESSENTIAL REFERENCE for every healthcare professional!
The carefully and thoroughly updated 9th edition of the South African Medicines Formulary (SAMF) is 
now available. It is your essential reference to rational, safe and cost-efficient use of  medicines. That 
is why you should not prescribe without it.
The newly published SAMF provides easy access to the latest, most scientifically accurate information 
– including full drug profiles, clinical notes and special prescriber’s points. The convenient pocket-size 
design enables you to fit it comfortably into your bag or hospital coat pocket – always at hand for ready 
reference.
WHY YOU SHOULDN’T BE WITHOUT THE SAMF 9TH EDITION
The new 9th edition of SAMF provides expanded information on key issues facing South African 
healthcare professionals today, including antiretrovirals, TB treatment guidelines, management 
guidelines for asthma and chronic heart failure, other common chronic conditions  and prescribing in 
sport.
• It presents practical, new approaches to the management of venomous bites and stings.
• It outlines extensively the acute adverse reactions to drugs of abuse, and their management. 
• It features new as well as existing drugs, indexed by both trade and generic names.
• It offers fresh insights into informed prescribing and carries cautionary guidelines on drug 
interactions and a range of special risk patients and conditions.
And, as always, you can rely on...
• the professional compilation and editing by a team from the Division of Clinical Pharmacology, 
UCT
• an independent and unbiased guide on prescribing in South Africa today
• the indication of agents included in the SA and WHO essential drug lists
• support of the SA national drug policy
• guidance for prescribing during pregnancy and lactation, and in patients with porphyria, liver 
disease and renal impairment (including tables with drug dosage adjustments); and 
• indexed and page tabs for quick and easy access to each section. 
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